Spots Global Cancer Trial Database for A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)
Official Title: A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)
Study ID: NCT00917306
Conditions
Interventions
Study Description
Brief Summary: The open label study is designed to assess the safety and efficacy of 0.05% PEP005 Gel when applied to an area of skin containing 4-8 AK lesions on non-head locations.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Park Avenue Dermatology, Orange Park, Florida, United States
Medaphase Inc, Newnan, Georgia, United States
Gwinnett Clinical Research Centre, Snellville, Georgia, United States
Michigan Center for Research Corp, Clinton Twp, Michigan, United States
Henry Ford Health Systems, Detroit, Michigan, United States
Dermatology Associates of Rochester, Rochester, New York, United States
Oregon Health and Science University, Portland, Oregon, United States
Dermatology Research Associates, Nashville, Tennessee, United States
Dematology on Ward, Adelaide, South Australia, Australia
Dermatology Institute of Victoria, Melbourne, Victoria, Australia
St John of God Dermatology, Subiaco, Western Australia, Australia
Contact Details
Name: Eugene Bauer, MD
Affiliation: Chief Medical Officer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
